GeneMe, a Gdańsk, Polish-based biotechnology company pioneering a universal molecular genetic tests platform, completed a €5.2M round of seed funding.
The round was led by Robin Tombs, Co-Founder of Yoti and previously of Gamesys, and other angel investors.
The company intends to use the funds to advance its platform and further refine its development of molecular NAAT COVID-19 tests: FRANKD, SAVD, and ICED and to consolidate emergency triage services by acquiring a minority stake in the medical-box startup Medicalls.
Led by Dawid Nidzworski, CEO, GeneMe is a Polish biotech company, producing services related to polymorphisms analysis and broadly defined genetic tests. A spin-off from The Institute of Biotechnology and Molecular Medicine (IBMM), the company has developed and patented a universal protein (polymerase) for RT-LAMP testing, which allows the production of accurate, rapid, molecular genetic COVID tests. The fusion of this patented DNA polymerase with NeqSSB protein allows GeneMe to produce enzymes that refine the testing process, enabling analysis to be specific and scalable for mass use.
FRANKD is CE IVD-approved and FDA EUA-applied, and its solution is already utilized in over twenty countries.